Bringing Innovation to Neglected Disease R&D - A new report highlights the industry's contributions to neglected diseases and calls for further collaboration. - BioPharm International

ADVERTISEMENT

Bringing Innovation to Neglected Disease R&D
A new report highlights the industry's contributions to neglected diseases and calls for further collaboration.


BioPharm International
Volume 25, Issue 10, pp. 56-57


(BIOVENTURES FOR GLOBAL HEALTH)
The mission of the nonprofit organization BIO Ventures for Global Health (BVGH) is to save lives by accelerating the development of novel drugs, vaccines, and diagnostics coming from the biopharmaceutical industry that address the unmet medical needs of the developing world. In March 2012, BVGH, in conjunction with the Biotechnology Industry Organizaton (BIO) released a report, Developing New Drugs and Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape, which included information about of the industry's participation in R&D for neglected diseases at the global level (1). The report showed that small- to medium-sized biotechnology companies are participating in a high percentage (41%) of projects targeting neglected diseases of the developing world. The findings of this report were surprising, given the financial risks these companies take on and the little to no promise of a return on their R&D investment.

Intrigued by the level of participation already among industry and stakeholders, BVGH joined forces with BIO to learn more about the biotech sector and its contributions to neglected-disease product development across drugs, vaccines, and diagnostics. Using updated product development data from the BVGH Global Health Primer, BVGH and BIO have authored a new report, Biotechnology: Bringing Innovation to Neglected Disease Research and Development, which not only reinforces the findings of the March Product Developer Landscape, but also sheds light on the mechanisms driving biotech participation in global health and makes recommendations for fully leveraging the innovation emerging from the biotech sector (2).

The following sections highlight the report's key findings and are based on the full BVGH and BIO report snapshot.

CURRENT INDUSTRY ENGAGEMENT

The following points summarize the work the biotech industry is currently doing in neglected disease R&D:

Partnering is an important driver. Sixty-four percent of all products in development by biotechnology companies across the pipeline of drugs, vaccines, and diagnostics for neglected diseases involve partnering.

Product development partnerships (PDPs) and government agencies are driving biotechnology company partnering for neglected diseases. PDPs are a unique public–private partnering mechanism to increase biopharmaceutical participation in neglected disease R&D. Biotechnology companies partner with academia, PDPs, government agencies, and other industry, to advance neglected disease R&D projects. PDPs are the second most frequent partner, after academia—PDPs are involved in 52% of partnered projects. When a PDP is not involved in a project, biotechnology-government partnerships increase, especially for vaccines and diagnostics.

For tuberculosis and dengue fever, biotechnology companies are often working independently. Across all neglected diseases, biotechnology companies work alone 36% of the time. For tuberculosis, 49% of projects are conducted alone and for dengue, 53% of projects are completed alone. Companies more frequently overcome barriers and leverage some market potential to work alone. For the other neglected diseases that have little or no market, such as leishmaniasis, African sleeping sickness, and Chagas disease, biotechnology companies can take advantage of strategic partnerships to increase their participation. Working alone is not encouraged per se, but this observation is aligned with the idea that the market barrier is significant for many of the neglected diseases that suffer from an insufficient market.

As noted in the report, products for tuberculosis and dengue fever may have some return on investment, especially in the private sector of emerging market countries based on demand and market analyses, which may allow the company to pursue the opportunity without partners.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here